Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients

J Cardiovasc Electrophysiol. 2012 May;23(5):515-20. doi: 10.1111/j.1540-8167.2011.02223.x. Epub 2011 Nov 14.

Abstract

Background: There are limited data regarding the incidence and prognostic significance of ventricular arrhythmias (VA) in ambulatory continuous flow left ventricular assist device (LVAD) patients.

Methods: Sixty-one consecutive patients from November 1, 2006 through December 31, 2010 with an LVAD and implantable cardioverter defibrillator that survived to discharge from the LVAD implantation admission were studied. Follow-up began from date of discharge with both devices in situ and ended with death, transplant, on June 1, 2011. Pre-LVAD VA history was related to the primary endpoints of post-LVAD VA, mortality, and the combined endpoint of post-LVAD VA/mortality.

Results: During a mean follow-up of 622 days 19 patients (31%) experienced VA (14 episodes of VT, 5 episodes of VF). Pre-LVAD VA was predictive of post-LVAD VA (hazard ratio [HR] 2.91, P = 0.026) and the combined post-LVAD VA/mortality endpoint (HR 2.70, P = 0.021) but only displayed a nonsignificant association with mortality (HR 2.30, P = 0.11). In multivariate analysis, pre-LVAD VA remained a significant predictor of post-LVAD VA (HR 2.84, P = 0.03) and the combined post-LVAD VA/mortality endpoint (HR 2.65, P = 0.025). Post-LVAD VA was the strongest univariate predictor of mortality (HR 13.92, P < 0.001) and remained so after multivariate adjustment (HR 9.69, P = 0.001). Post-LVAD VA occurred at a mean of 1 year from mortality events with 45% within 1 month.

Conclusions: Pre-LVAD VA is a significant predictor of post-LVAD VA but not of mortality. VA in the continuous flow LVAD population carries a significant risk of mortality often within the first month.

MeSH terms

  • Adult
  • Aged
  • Ambulatory Care*
  • Chi-Square Distribution
  • Death, Sudden, Cardiac / epidemiology*
  • Death, Sudden, Cardiac / prevention & control
  • Defibrillators, Implantable* / adverse effects
  • Female
  • Heart Failure / mortality*
  • Heart Failure / physiopathology
  • Heart Failure / therapy
  • Heart-Assist Devices* / adverse effects
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Minnesota / epidemiology
  • Multivariate Analysis
  • Proportional Hazards Models
  • Prosthesis Design
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Tachycardia, Ventricular / mortality*
  • Tachycardia, Ventricular / physiopathology
  • Tachycardia, Ventricular / therapy
  • Time Factors
  • Treatment Outcome
  • Ventricular Fibrillation / mortality*
  • Ventricular Fibrillation / physiopathology
  • Ventricular Fibrillation / therapy
  • Ventricular Function, Left*